Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.

Zaccarelli, Mauro; Perno, Carlo Federico; Forbici, Federica; Soldani, Fabio; Bonfigli, Sandro; Gori, Caterina; Trotta, Maria Paola; Bellocchi, Maria Concetta; Liuzzi, Giuseppina; D'Arrigo, Roberta; De Longis, Patrizio; Boumis, Evangelo; Bellagamba, Rita; Tozzi, Valerio; Narciso, Pasquale; Antinori, Andrea.
Clin Infect Dis; 38(3): 433-7, 2004 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-14727218
Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.
Selo DaSilva